Matrubials vs Isomorphic Labs

Side-by-side comparison of features, pricing, and ratings

Analysis reviewed Live tool data as of 2026-10-18
Cross-checked through our multi-step verification ·
Saved

At a glance

DimensionMatrubialsIsomorphic Labs
PricingContact (likely early-stage grant/investor funded)Contact (likely $M+)
Target AudienceResearchers, women's health, biotech investorsBig pharma partners
StagePreclinical, early-stage R&DPartnerships with Novartis & J&J, Series B (2026)
Key TechnologyAI platform for antimicrobial peptides from milk proteinsAlphaFold + proprietary Drug Design Engine for small molecules
Clinical FocusBacterial Vaginosis, antimicrobial resistanceBroad drug discovery (multiple therapeutic areas via partners)

Isomorphic Labs is the heavyweight for big pharma-scale AI drug discovery, backed by DeepMind's AlphaFold and massive funding; Matrubials is a niche, early-stage biotech leveraging AI on milk proteins for antimicrobial peptides. Choose Isomorphic if you have a $B+ pipeline and need predictive modeling; choose Matrubials if you're researching BV alternatives or interested in natural peptide therapeutics. Matrubials is not yet for direct clinical use, while Isomorphic is operationally mature.

Matrubials
Matrubials

Matrubials is a UC Davis spin-off developing AI-identified antimicrobial peptides from mammalian milk, starting with a topical therapy for Bacterial Vaginosis.

Visit Website
Isomorphic Labs
Isomorphic Labs

Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.

Visit Website
Pricing
Contact Sales
Contact Sales
Plans
—
—
Popularity
7 views
7.5k views
Skill Level
Advanced
Advanced
API Available
Platforms
—
—
Categories
🧬 Drug Discovery & Life Sciences
🧬 Drug Discovery & Life Sciences
Features
AI-enabled identification and validation of bioactive peptides from mammalian milk
Antimicrobial peptides derived from mammalian milk proteins developed as antibacterial therapeutics
Selective mechanism designed to target pathogens while sparing beneficial microbiota
Lead program: topical therapeutic for Bacterial Vaginosis (BV)
Platform positioned to address non-selectivity and emerging antimicrobial resistance
Preclinical-stage pipeline with no commercial products
Women's health as the initial therapeutic focus
Platform aimed at indications impacting all genders and ages
Discovery approach inspired by the protective role of milk in newborns
Team drawn from the UC Davis Foods For Health Institute
Combined 100 years of microbiology, chemistry and food science experience among founders
Headquartered in Davis, California
Topical route of administration intended to limit microbiome disruption versus systemic antibiotics
Pipeline targeting bacterial infections broadly, not a single pathogen class
Drug Design Engine spanning generative molecule design through lead optimization
Predictive AI models that anticipate how candidate drugs will perform
Generative models for designing novel molecules
Built on and beyond the Nobel-winning AlphaFold system
End-to-end research collaborations from target identification to lead optimization
Digital biology approach aimed at discovery at digital speed
Named pharma partners include Johnson & Johnson, Novartis and Eli Lilly
Joined the Virtual Biology Initiative to build foundational data for AI disease models
Funder of Biohub's $1.8B initiative to train AI models that predict cell behavior
Bioresilience framework for biological threats and health emergencies
Announced a new path to making medicines with AI
Series B announced May 2026 to scale the Drug Design Engine
Follows a $600M external raise in March 2025
President Max Jaderberg appointed November 2025 to integrate AI and science
Founded by Demis Hassabis, who serves as CEO

Who should pick which

  • Big pharma R&D head
    Pick: Isomorphic Labs

    Isomorphic's proven partnership model (Novartis, J&J), Series B funding, and AlphaFold-based platform can accelerate large-scale drug development programs.

  • Academic researcher studying antimicrobial peptides
    Pick: Matrubials

    Matrubials' AI platform focusing on milk protein-derived peptides aligns with academic research on natural antimicrobials, and UC Davis collaboration offers potential access.

  • Women's health biotech investor
    Pick: Matrubials

    Matrubials targets Bacterial Vaginosis with a selective peptide approach, addressing a large unmet need with minimal disruption to microbiome.

  • Solo startup founder in drug discovery
    Pick: Matrubials

    Neither is ideal, but Matrubials' smaller scale and academic ties may offer collaboration or licensing opportunities with lower barriers than Isomorphic's enterprise model.

  • Pharma executive seeking late-stage pipeline AI
    Pick: Isomorphic Labs

    Isomorphic's predictive models and generative design engine are built for late-stage lead optimization, backed by deep expertise and resources.

Frequently Asked Questions

Matrubials vs Isomorphic Labs: which should you choose?

Isomorphic Labs is the heavyweight for big pharma-scale AI drug discovery, backed by DeepMind's AlphaFold and massive funding; Matrubials is a niche, early-stage biotech leveraging AI on milk proteins for antimicrobial peptides. Choose Isomorphic if you have a $B+ pipeline and need predictive modeling; choose Matrubials if you're researching BV alternatives or interested in natural peptide therapeutics. Matrubials is not yet for direct clinical use, while Isomorphic is operationally mature.

Which tool is more mature for drug discovery partnerships?

Isomorphic Labs, with partnerships with Novartis and J&J, Series B funding, and over $600M raised, is far more mature than Matrubials which is preclinical.

Can I use either tool as an individual researcher?

Neither offers self-serve access. Isomorphic only partners with large pharma; Matrubials may collaborate with academic researchers through UC Davis.

Does Isomorphic Labs offer a product for small molecule screening?

Yes, their Drug Design Engine combines predictive and generative AI for protein-ligand interactions, but only through partnerships.

What disease areas does Matrubials focus on?

Primarily Bacterial Vaginosis (BV), with potential for other infectious diseases. Their peptides are topical and aim to reduce antibiotic resistance.

Are these tools FDA-approved?

No. Isomorphic's partners handle clinical trials; Matrubials is preclinical. Neither has an approved drug.

What is the latest funding news for Isomorphic Labs?

Isomorphic raised a $600M external round in 2025 and a Series B in February 2026 (amount undisclosed).

Does Matrubials use AlphaFold?

No. Matrubials uses its own AI platform for antimicrobial peptide discovery, not AlphaFold.

Which tool is better for antimicrobial resistance?

Matrubials directly targets antimicrobial resistance with selective peptides; Isomorphic's broad discovery platform could also address resistance but isn't its focus.

More Matrubials or Isomorphic Labs comparisons

Explore each tool further

Browse these categories

Still deciding? Get the weekly AI tools brief

One email a week — new tools, honest comparisons, no spam.

Last reviewed: July 3, 2026